Holen Sie sich die Stockscreener-App
1.28
0.79%
0.01
Schlusskurs vom Vortag:
$1.27
Offen:
$1.28
24-Stunden-Volumen:
742.52K
Relative Volume:
0.21
Marktkapitalisierung:
$110.50M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.4444
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+15.32%
1M Leistung:
-9.22%
6M Leistung:
-61.33%
1J Leistung:
-77.18%
1-Tages-Spanne:
$1.25
$1.3059
1-Wochen-Bereich:
$1.08
$1.45
52-Wochen-Spanne:
$0.9101
$6.69
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.28 | 110.50M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Acquired by Raymond James Financial Inc. - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Top 5 CRISPR Companies To Invest In (April 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan
Zacks Research Forecasts Editas Medicine FY2027 Earnings - MarketBeat
Gene Editing Market Detailed In New Research Report 2025-2032 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough - simplywall.st
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
The Escalator: Bristol Myers Squibb, Editas Medicine, Takeda and more - Medical Marketing and Media
Editas Medicine, Inc. (NASDAQ:EDIT) Sees Large Drop in Short Interest - MarketBeat
Dyne names Editas’ Erick Lucera CFO - biocentury.com
Gene Editing Market Demand, Growth and Future Scope 2025-2032 | - openPR
AstraZeneca deepens China investment; Editas loses CFO to Dyne - Yahoo Finance
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Gene Editing Market Is Booming Worldwide 2025-2032 | CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics - openPR
Editas Medicine appoints new CFO amid executive reshuffle By Investing.com - Investing.com Canada
Editas Medicine Announces CFO Transition - TipRanks
Editas Medicine appoints new CFO as Lucera steps down By Investing.com - Investing.com Australia
Editas Medicine appoints new CFO amid executive reshuffle - Investing.com
Editas Medicine Announces Chief Financial Officer Transition -March 20, 2025 at 04:45 pm EDT - Marketscreener.com
Editas Medicine appoints new CFO as Lucera steps down - Investing.com
Editas Medicine Announces Chief Financial Officer Transition - GlobeNewswire
Editas Medicine Promotes Finance VP to CFO: What Her 18-Year Track Record Means for EDIT - Stock Titan
Genome Editing Tools Market Set for Major Expansion as Gene - openPR.com
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Monaco Asset Management SAM Takes $1.36 Million Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Average Target Price from Brokerages - MarketBeat
Editas Medicine Reports Progress in Gene Editing - TipRanks
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely - Yahoo Finance
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility By Investing.com - Investing.com South Africa
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility - Investing.com
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Analysts - Defense World
Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations - TipRanks
Editas at Barclays Healthcare Conference: Gene Editing Ambitions - Investing.com
Editas Medicine at Leerink’s Global Healthcare Conference: In Vivo Focus By Investing.com - Investing.com Canada
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):